Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Prog Cardiovasc Dis. 2023 Oct 17;81:2–9. doi: 10.1016/j.pcad.2023.10.003

Fig. 4.

Fig. 4.

Results from two recent trials and two recent meta-analyses conclusively demonstrated the cardio-protective and kidney-protective effects of SGLTi in HF and CKD populations. The absolute benefits convincingly outweighed the potential harms.15 Permission obtained.